KPTI Stock — Karyopharm Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.05

Market cap

$1.2M

Cash

$65.1M

Enterprise value

-$63.9M

Balance sheet

Cash	$65.1M
Debt	$0.0M
Net cash	$65.1M
Enterprise value	-$63.9M
Basic shares	22.7M shares
Fully diluted shares	45.8M shares
Fully diluted market cap	$2.3M
Cash per share	$2.87
Quarterly burn	$24.9M
Cash runway	2.6 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

22.7M

Pre-funded warrants

3.4M

Options

0.5M

RSUs

5.2M

Warrants

14.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

45.8M

Cap table as of 2026-08-06.

Price history

Loading KPTI daily closes…

Loading price history…

Next catalyst

Selinexor · Now - Nov 24, 2026 Now · Phase 2 · Myelofibrosis

Recently reported

selinexor Phase 3 Negative · 2026-07-30

XPORT-EC-042 · TP53 wild-type advanced/recurrent endometrial cancer (maintenance)

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Selinexor	Phase 2	Myelofibrosis	—
GUIDEDEst. Nov 7, 2026 Now half midpoint	selinexor SENTRY-2 Phase 2 (60 mg cohort, myelofibrosis) · NCT05980806	Phase 2	Not disclosed	H2 2026
GUIDEDNow - Dec 31, 2026 Now	selinexor SENTRY Phase 3 in JAKi-naive myelofibrosis	Phase 3	JAKi-naive myelofibrosis	Q4 2026
Jan 12 - Feb 23 in 9 wks	Selinexor (combination therapy)	Phase 3	Relapsed/Refractory Diffuse Large B-cell Lymphoma	—
Jan 12 - Feb 23 in 9 wks	Selinexor	Phase 2	Diffuse Large B-cell Lymphoma	—
May 13 - Jun 24 in 6 mo	Selinexor	Phase 2	Multiple Myeloma	—
Jul 13 - Aug 24 in 8 mo	Selinexor 60 mg	Phase 2	Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia	—
Feb 12 - Mar 25 in 15 mo	Selinexor	Phase 2	Multiple Myeloma, Refractory	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Selinexor (XPOVIO)

Approved · Active Modality: small molecule (XPO1 inhibitor)

Aliases NEXPOVIO

Target XPO1

Partnerships Antengene: Asia-Pacific; Menarini/Berlin-Chemie: Europe, Latin America, Middle East/Africa; KKR (ex-HCRx): revenue interest financing (percentage of selinexor net revenues, capped at $263.3M)

Indications

Multiple myeloma (with bortezomib + dexamethasone, >=1 prior therapy) (Stage not disclosed)
Relapsed/refractory multiple myeloma (with dexamethasone, >=4 prior therapies) (Stage not disclosed)
Myelofibrosis (with ruxolitinib, JAKi-naive) (Phase 3)
Myelofibrosis (monotherapy, JAKi-naive, moderate thrombocytopenia) (Phase 2)
Previously treated multiple myeloma (all-oral, with pomalidomide + dexamethasone) (Phase 3)
Relapsed/refractory DLBCL (Stage not disclosed)
TP53 wild-type advanced/recurrent endometrial cancer (maintenance) (Phase 3)

Catalysts

— August 2026
— H2 2026
— H2 2026

Status note DLBCL accelerated approval voluntarily withdrawn March 2026; company-sponsored trials in that indication being terminated. Myelofibrosis sNDA planned August 2026. Endometrial cancer Phase 3 (XPORT-EC-042) under evaluation.

Eltanexor

Stage not disclosed · Active Modality: small molecule (next-generation XPO1 inhibitor)

Target XPO1

Indications

Myeloproliferative neoplasms (Stage not disclosed)

Status note Company plans to explore development in additional myeloproliferative neoplasms, subject to obtaining additional funding.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Selinexor
Lead indication	Myelofibrosis
Lead phase	Phase 3
Active trials	8
Collaborator trials	15

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04442022	Phase 3	Active, not recruiting	Sponsor	KPTI	—	Relapsed/Refractory Diffuse Large B-cell Lymphoma	—
NCT04562389	Phase 3	Active, not recruiting	Sponsor	KPTI	—	Myelofibrosis	Q4 2026
NCT05611931	Phase 3	Active, not recruiting	Sponsor	KPTI	—	Endometrial Cancer	—
NCT02227251	Phase 2	Active, not recruiting	Sponsor	KPTI	—	Diffuse Large B-cell Lymphoma	—
NCT02343042	Phase 2	Recruiting	Sponsor	KPTI	BMY	Multiple Myeloma	—
NCT05980806	Phase 2	Recruiting	Sponsor	KPTI	—	Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia	H2 2026 Est. Nov 7, 2026 · half midpoint
NCT04414475	Phase 2	Recruiting	Sponsor	KPTI	—	Multiple Myeloma, Refractory	—
NCT04562870	Phase 2	Active, not recruiting	Sponsor	KPTI	—	Myelofibrosis	—
NCT05028348	Phase 3	Active, not recruiting	Collaborator	European Myeloma Network B.V.	—	Multiple Myeloma	—
NCT02436707	Phase 2	Active, not recruiting	Collaborator	Canadian Cancer Trials Group	JNJ	Lymphoma	—
NCT07479979	Phase 2	Recruiting	Collaborator	Natalie Callander	SNY	Relapse Multiple Myeloma; Refractory Multiple Myeloma	—
NCT05530421	Phase 2	Recruiting	Collaborator	University of Miami	—	Relapsed and Refractory Multiple Myeloma	—

Sponsor-matched active trials from ClinicalTrials.gov (8 as sponsor, 15 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 23 active trials for Karyopharm Therapeutics Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	1,917,354	no change	0.16%	2026-08-14
Boxer Capital	302,536	no change	0.22%	2026-08-14
ADAR1 Capital Management	0	-136,736	0.00%	2026-08-14
Ikarian Capital	0	-733,435	0.00%	2026-08-14
DAFNA Capital	0	-45,800	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KPTI — Karyopharm Therapeutics Inc. ☆